The FDA Has Accepted And Granted Priority Review To The Biologics License Application For Daiichi Sankyo/Merck's Patritumab Deruxtecan For Pretreated Locally Advanced Or Metastatic EGFR-Mutated Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted and granted priority review to Daiichi Sankyo and Merck's joint Biologics License Application for patritumab deruxtecan, a treatment for EGFR-mutated non-small cell lung cancer.
December 22, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daiichi Sankyo's patritumab deruxtecan, developed with Merck, received FDA priority review for treating EGFR-mutated non-small cell lung cancer.
FDA priority review is a positive regulatory milestone, likely to expedite the approval process and enhance the credibility of Daiichi Sankyo's product, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 80
POSITIVE IMPACT
Merck, in collaboration with Daiichi Sankyo, has had their joint Biologics License Application for patritumab deruxtecan accepted for priority review by the FDA.
The FDA's priority review of patritumab deruxtecan, which Merck is co-developing with Daiichi Sankyo, is likely to be seen as a positive development by investors, potentially leading to a short-term uptick in Merck's stock price due to anticipated market advantage and revenue growth from the new treatment.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 80